CN1823815A - Application of sodium sulfide vein injection liquid in preparation of medicine for treating sequela of cerebral embolism death - Google Patents
Application of sodium sulfide vein injection liquid in preparation of medicine for treating sequela of cerebral embolism death Download PDFInfo
- Publication number
- CN1823815A CN1823815A CN 200510053319 CN200510053319A CN1823815A CN 1823815 A CN1823815 A CN 1823815A CN 200510053319 CN200510053319 CN 200510053319 CN 200510053319 A CN200510053319 A CN 200510053319A CN 1823815 A CN1823815 A CN 1823815A
- Authority
- CN
- China
- Prior art keywords
- sodium sulfide
- injection liquid
- treatment
- medicine
- vein injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
An application of the venous injection of sodium sulfide in treating the sequelae of cerebral infarction, such as aphasia, hemiplegia, dementia, etc, by suppressing the release of serozyme is disclosed.
Description
China has patients with cerebrovascular disease to reach 500--600 ten thousand at present approximately, dies from about 1,000,000 people of this disease every year, and annual new cases about 1,500,000.Wherein 75% has the different labor Disability, and severe disabled person's (aphasia, hemiplegia, dementia) reaches more than 40%.The treatment in time of racing against time is to prevent the unique channel that disables.Now world medical circle is consistent thinks, the timely treatment that takes place in back 6 hours at cerebral infarction is vital, is called " treatment window " during this period of time ", promptly its prognosis of effective treatment during this period of time is better.Then therapeutic effect is relatively poor to surpass 6 hours.Therefore breaking through " 6 hours treatment windows ", seeking new more efficient drug is the important subject of whole world medical circle always.
Same, present used intravenous pharmacy on the treatment cerebral infarction sequela, for example Ginaton, arasaponin, calcium antagonist class, flavonoid, enzyme or polypeptide class or the like are chemosynthesis or natural organic extract (all carbon elements).Whole world medical circle does not also have a kind of application inorganic salt (not carbon elements) to treat the medicine appearance of cerebral infarction sequela at present.
The used organic drug of above-mentioned vein has following three unsurmountable shortcomings: 1. the medicine of chemosynthesis, and environmental pollution is inevitable, the cost height; And it is poor to 15 days later clinical efficacies of cerebral infarction sequela.2. the medicine of plant extract, owing to the medical material place of production, receive territory, fief difference, so quality standard is difficult to control, the uncertainty of effective ingredient must cause the uncertain of curative effect.3. present, the medicine great majority for the treatment of cerebral infarction clinically all had curative effect preferably in 6 hours, but surpass after 15 days treatment to the sequela left over then be close to invalid.
The present invention has following two distinguishing features, and 1. the medicine of treatment cerebral infarction sequela belongs to the not inorganic drug of carbon elements; 2. even if surpass 15 days, this medicine still has better curative effect to the treatment of cerebral infarction sequela.
Finished product of the present invention is faint yellow clear and bright solution.This product has the effect of definite detoxifcation, blood stasis dispelling and raising immunity.Be used for the treatment when all medicines are not imitated after the cerebral infarction sequela 15 days.Points for attention forbid mixing use with other medicines in the process of splashing into.
The present invention's zoopery and 100 examples (establishing arasaponin 40 routine matched groups) clinical practice confirms this product determined curative effect, and definite blood stasis dispelling effect is arranged, and has no side effect in therapeutic dose.The pharmacological results is as follows:
1. white mice (subcutaneous) LD
50, the credible 194.6～244.6mg/kg that is limited to, injected dose is the following person of 130mg/kg, the movable no abnormal performance of mice.
2. sub-acute toxicity test: get blood by healthy white rat posterior auricular vein clump, measure erythrocyte, leukocyte, hematochrome, hematocrit, hematoblastic content respectively with micro-blood counting instrument; Measure the animal electrocardiogram with leading physiograph (KM--6004) more; Measure the transaminase with the substrate method; Measure blood urea nitrogen with diacetyl-oxime method.Random packet then, (1). heavy dose of group 36ml/kg, dosage group 18ml/kg in (2), (3) small dose group 9ml/mg, (4) matched group 0.9% sodium chloride solution, 6ml/kg.More than each the group be intraperitoneal administration, once a day.Respectively get blood once in the time of 45 days, 90 days, measure corresponding index and do corresponding inspection.The result is as follows: compare before the index of surveying and the administration and there is no ANOMALOUS VARIATIONS, got animal on the 90th day extremely and take out the heart, liver, lung, kidney, adrenal gland, brain, testis, epididymis, uterus and ovary, each is organized ponderal index and histopathologic examination and compares with matched group and there is no ANOMALOUS VARIATIONS.
Other change as, body weight gain percentage rate, renal function (BUN) no abnormality seen, decrease and GPT is counter, and this shows that this product has the certain protection effect to liver.Do not see ascites and exudate after cutting open the belly in 90 days, illustrate that drug absorption is good.Whole experiment overall process does not have animal dead.
3. the arterial wall severe trauma to causing behind the animal aortic cannulation has activated a large amount of prothrombings and other thrombins, and the platelet disintegrate forms girder, the cellulose network a large amount of erythrocyte and form thrombosis.This product plays the obvious suppression effect to the release of prothrombing.Thrombosis is obviously reduced---the blood stasis dispelling effect.
Embodiment 1. prescriptions consist of: injection sodium sulfide 0.1 gram, and sodium chloride 0.9 gram, 25 milliliters of propylene glycol, water for injection add to 100 milliliters.Require to make 5 milliliters/injection according to the injection small-volume injection, standby behind the routine disinfection.
Embodiment 2. usings method are: splashed into slowly by vein in 250～350 milliliter of 5% glucose solution of each 5～10 milliliters of addings, every day 1 time, 10 days is a course of treatment.
Embodiment 3. purposes are the curative effects of observing sodium sulfide vein injection liquid treatment cerebral infarction sequela (a month later convalescent period).Method: (male's 52 examples, women's 48 examples at the age 60 ± s12a), give sodium sulfide vein injection liquid 30mgiv, drip, qd to sodium sulfide vein injection liquid group 100 examples.Arasaponin matched group 40 examples (male's 21 examples, women's 19 examples, age 60a ± 10a) give XUESAITONG (Radix Notoginseng total arasaponins) injection 30mg iv, drip, qd.Be ten days a course of treatment.Be a total course of treatment three courses of treatment.The result: the sodium sulfide injection group cures 38% substantially, always effectively heals 90%; Matched group 5%, and 28%, significant differences (p＜0.01) is arranged.Sodium sulfide injection group treatment back each index of hemorheology and triacylglycerol obviously reduce, and infarct size obviously dwindles (p＜0.01), with matched group significant differences (p＜0.01) is arranged relatively.
Embodiment 4.
Mr. Wang man 56 years old.Ruicheng, the Shanxi Province cadre of bureau of agriculture.In August, 1997, cerebral infarction showed effect for the second time, lived local hospitalize 33 days, and all medicines are not imitated and examined: the mind stupor, swallowing reflex disappears, the nasal feeding stomach tube.Import sodium sulfide vein injection liquid 30mg (add among the 5% glucose 350ml, vein splashes into) at once, after this once a day.Can know the people in second day, take out stomach tube on the 4th day, oneself is the influent stream food separately.But the 5th day out-of-bed activity, leave hospital a course of treatment (10 days), modern alive.
Mrs Hu woman 69 years old.The Linfen rail man.301 Hospital is diagnosed as through Beijing: the degeneration of cerebellum infarction Nux Canarii albi.Be unable to leave the bed 1 year surplus, all medicines are not imitated.Examine in July, 2002: wheelchair, the depleted shape of becoming thin.Mind is clear, language unable (shape of the mouth as one speaks voiceless sound is arranged), " cervical flaccidity " (head can not uprightly), nocturia 6～8 times.Import sodium sulfide vein injection liquid 30mg (add among the 5% glucose 350ml, vein splashes into) at once, after this once a day.After 15 days, nocturia 2～3 times, it is ruddy that complexion is changeed, and head can be upright.After 3 courses of treatment (30 days), 7 kilograms of weight increase, lamprophonia, it is far away to lead under the finger situation 10 meters of walkings the people.Now still in after treatment.
Ms Zhang woman 65 years old.Shanxi Houma City Qiao Cun people.Work prominent sense dizziness when buying vegetables a day morning in August, 2002, walking immediately is to certain factory's hospital admission.The CT film making turns out to be cerebral infarction.20 days gently not counter the increasing the weight of of the state of an illness that are hospitalized for treatment, the paralysis of right side upper and lower extremities.Stretcher is unable to leave the bed after sending back home, and the back began input sodium sulfide vein injection liquid 30mg (add among the 5% glucose 350ml, vein splashes into) on the 16th day, once a day.Can drink from pouring down by bed after the 7th day, can lean on crutch and walk 100 meters far away in the 10th day.Have a rest and imported second course of treatment again in 7 days, after this promptly return to one's perfect health and play mahjong and live an easy life in old age.
Woman Zhao young men and women 68 years old.Houma City Pingyang pharmacist of worker's hospital of machinery plant.Suffer from cerebral hemorrhage in April, 2002, through emergency escape, and existing paralysis bed 12 months, (also live this city hospital rehabilitation center around here, never stopped treatment) examined on April 10th, 2003: mind is clear, the language profit, but the left limb activity can not.Nocturia 6～7 times.Import sodium sulfide vein injection liquid 30mg (add among the 5% glucose 350ml, vein splashes into) at once, after this once a day.Later can hold up out-of-bed activity by the people, nocturia 1 time 2 courses of treatment (20 days).After finished 3 courses of treatment, slowly 15 meters of walkings were far away can to lean on crutch.
Claims (2)
1. the application of sodium sulfide vein injection liquid in the medicament of preparation treatment cerebral infarction sequela (aphasia, hemiplegia, dementia).
2. sodium sulfide vein injection liquid requires vein slowly to splash into when preparation treatment cerebral infarction sequela.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510053319 CN1823815A (en) | 2005-02-26 | 2005-02-26 | Application of sodium sulfide vein injection liquid in preparation of medicine for treating sequela of cerebral embolism death |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510053319 CN1823815A (en) | 2005-02-26 | 2005-02-26 | Application of sodium sulfide vein injection liquid in preparation of medicine for treating sequela of cerebral embolism death |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1823815A true CN1823815A (en) | 2006-08-30 |
Family
ID=36934755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510053319 Pending CN1823815A (en) | 2005-02-26 | 2005-02-26 | Application of sodium sulfide vein injection liquid in preparation of medicine for treating sequela of cerebral embolism death |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1823815A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040861A (en) * | 2012-12-07 | 2013-04-17 | 苏州大学 | Application of hydrogen sulfide releasing agent in preparation of medicament for treating renal fibrosis disease |
| CN106983773A (en) * | 2017-04-14 | 2017-07-28 | 绵阳思明科技有限公司 | Application, preparation method and detection device of the sodium sulfide vein injection liquid in the medicine for preparing treatment AIDS virus |
| CN107028979A (en) * | 2017-04-14 | 2017-08-11 | 绵阳思明科技有限公司 | A kind of preparation method for anti-acute cerebral ischemia medicine, using and detection device |
-
2005
- 2005-02-26 CN CN 200510053319 patent/CN1823815A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040861A (en) * | 2012-12-07 | 2013-04-17 | 苏州大学 | Application of hydrogen sulfide releasing agent in preparation of medicament for treating renal fibrosis disease |
| CN106983773A (en) * | 2017-04-14 | 2017-07-28 | 绵阳思明科技有限公司 | Application, preparation method and detection device of the sodium sulfide vein injection liquid in the medicine for preparing treatment AIDS virus |
| CN107028979A (en) * | 2017-04-14 | 2017-08-11 | 绵阳思明科技有限公司 | A kind of preparation method for anti-acute cerebral ischemia medicine, using and detection device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Winokur et al. | Withdrawal reaction from long-term, low-dosage administration of diazepam: A double-blind, placebo-controlled case study | |
| Mawdsley | Treatment of Parkinsonism with Laevo-dopa | |
| Slatkin et al. | Donepezil in the treatment of opioid-induced sedation: report of six cases | |
| Gelenberg et al. | Psychoses | |
| KR19980701640A (en) | Use of Melatonin for the Treatment of Pharmaceutical Addiction Patients | |
| WO2013189285A1 (en) | Application of piceatannol-3'-o-β-d-glucopyranoside in preparation of medicaments for improving microcirculation block | |
| JP2001513814A (en) | Use of levobupivacaine in pediatric surgery | |
| CN1823815A (en) | Application of sodium sulfide vein injection liquid in preparation of medicine for treating sequela of cerebral embolism death | |
| MX2007003948A (en) | Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management. | |
| WO2020143746A1 (en) | Use of chlorogenic acid in preparing medicine or pharmaceutical composition for preventing or treating pain | |
| CN105213321B (en) | A kind of medicinal-bathing particle agent and application thereof of qinghaosu or derivatives thereof | |
| US20230077724A1 (en) | Methods and compositions for treating cannabinoid overdose with a cannabinoid receptor antagonist | |
| SE516468C2 (en) | Use of an extract from Morinda citrifolia L. for the preparation of drugs for the treatment of tinnitus. | |
| Sadarmin et al. | An unusual case of butcher's broom precipitating diabetic ketoacidosis | |
| KR101864384B1 (en) | Composition and Method for Treating, relieving or Preventing Muscle Cramps | |
| CN1875968B (en) | Application of anisodamine in preparation of smoking-stopping medicament | |
| CN101850031B (en) | Pueraria isoflavone capsule | |
| WO2011035500A1 (en) | Use of piperphentonamine or salts thereof in manufacture of medicaments for preventing / treating brain diseases | |
| Trope et al. | Systemic absorption of topical and subconjunctival gentamicin. | |
| Tyagi et al. | Ketamine—a review of published cases | |
| Robinson et al. | Effects of naltrexone on amphetamine choice in rhesus monkeys and rats. | |
| Gaylis, H. & Kaplan | Acute vascular insufficiency in the lower extremities associated with methysergide therapy for migraine | |
| Carvajal et al. | Antipsychotic drugs | |
| Lingjærde | Clinical experiences with thioproperazine (“Majeptil”) in chronic schizophrenia, psychotic excitation, and senile agitation | |
| Vaughan | The role of chlorpromazine in the management of psychiatric patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |